Black Africans, hepatitis C virus, antiviral therapy, genotype 4.
Abstract :
[en] Aim : To compare responses to therapy of Black African (BA)
and non-Black African (non- BA) patients with hepatitis C virus
genotype 4 (HCV-4) residing in Belgium.
Methods : In this retrospective multicenter study, 473 patients
with HCV-4 were selected from databases at 7 Belgian centers ;
209 treatment-naïve patients (154 BA) had received treatment with
peg-interferon (peg-IFN) plus ribavirin (RBV) and were included
in the study.
Results : There was a greater percentage of female patients in the
BA group than in the non- BA group ; BA patients were also older,
had a greater body mass index, and more frequently had abnormal
glucose metabolism. The route of contamination was more frequently
unknown in BA than in non-BA patients and BA patients
had more HCV-4 subtypes. There were no differences in other demographic
factors between the groups. Sustained viral response
(SVR) and complete early viral response rates were significantly
lower and relapse rates significantly higher in BA than in non-BA
patients. There were no differences between groups in rates of dose
modification or in drug tolerance.
Conclusion : In our cohort, treatment-naïve BA patients with
HCV-4 who were treated with peg-IFN and ribavirin had a much
lower SVR rate than treatment-naïve non-BA patients with HCV-
4 who were treated with peg-IFN and ribavirin, and a higher
relapse
rate, possibly related to a weaker response to interferonbased
therapy. Treatment may need to be adapted in this population.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Nkuize, M
Mulkay, JP
Adler, M
Lasser, L
Michielsen, P
de Galocsy, C
Assene, C
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Language :
English
Title :
Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin
Madhava V., Burgess C., Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis., 2002, 2: 293-302.
Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology, 2002, 36: S21-S29.
Kamal S.M., Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology, 2008, 47: 1371-1383.
Kamal S.M., El Kamary S.S., Shardell M.D., Hashem M., Ahmed IN., Muhammadi M. et al. Pegylated interferon alpha-2b plus ribavirine in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology, 2007, 46: 1732-1740.
Roulot D., Bourcier V., Grando V., Deny P., Baazia Y., Fontaine H. et al. Epidemiological profile and response to peginterferon Acta Gastro-Enterologica Belgica, Vol. LXXVI, July-September 2013 plus ribavirine treatment of hepatitits C virus genotype 4 infection. J. Viral Hepat., 2007, 14: 460-467.
Conjeevaram H.S., Fried M.W., Jeffers L.S., Terrault N.A., Wiley-Lucas T.E., Afdhal N. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology, 2006, 131: 470-477.
Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., Rossaro L., Ankoma-Sey V., Hamzeh F.M. et al. Peginterferon alpha-2a and ribavirin in Latino and Non-Latino whites with hepatitis C. N. Engl. J. Med., 2009, 360: 257-267.
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Intern. Med., 2004, 140: 370-381.
Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology, 2008, 134: 416-423.
Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461: 399-401.
Consensus panel. European society for the study of liver international consensus conference of hepatitis C. Paris 26-28 fevier 1999. Consensus statement J. Hepatol., 1999, 30: 956-961.
NIH Consensus statement on management of hepatitis C: 2002. NIH Consens state sci statements, 2002, 19: 1-46.
Michielsen P., Brenard R., Bourgeois N. Screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-19.
Reimer J., Schulte B., Castells X., Schafer I., Polywka S., Hedrich D. et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin. Infect. Dis., 2005, 40 Suppl 5: S373-S378.
Langlet P., D'Heygere F., Henrion J., Adler M., Delwaide J., Van Vlierberghe H. et al. A randomised trial of pegylated-interferonalpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients. Aliment. Phamacol. Ther., 2009, 30: 352-363.
Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology, 1996, 24: 289-293.
Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41: 1313-1321.
Moreno C., Deltenre P., Pawlotsky J.M., Henrion J., Adler M., Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J. Hepatol., 2010, 52: 25-31.
Tai A.W., Chung R.T. Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol., 2009, 50: 412-420.
Donlin M.J., Cannon N.A., Yao E., Li J., Wahed A., Taylor M.W. et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol., 2007, 81: 8211-8224.
He X.S., Ji X., Hale M.B. Global transcriptional response to interferon is a determinate of HCV treatment outcome and is modified by race. Hepatology, 2009, 44: 352-359.
Asselah T., De Muynck S., Broët P., Masliah-Planchon J., Blanluet M., Bièche I. et al. IL 28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol., 2012, 56 (3): 527-532.
Harris R.A., Sugimoto K., Kaplan D.E., Ikeda F., Kamoun M., Chang K.M. Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology, 2008, 48: 70-79.
Oleksyk T.K., Thio C.L., Truelove A.L., Goedert J.J., Donfield S.M., Kirk G.D. et al. Single nucleotide polymorphisms and haplotypes in IL10 region associated with HCV clearance. Genes Immun., 2005, 6: 347-357.
Rauch A., Laird R., McKinnon E., Telenti A., Furrer H., Weber R. et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens, 2007, 69: 237-240.
Torriani F.J., Rodriquez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 2004, 351: 438-450.
Martín-Carbonero L., Puoti M., García-Samaniego J., De Luca A., Losada E., Quinzan G. et al. Response to pegylated interferon plus ribavirin in HIV-Infected patients with chronic hepatitis C due to Genotype 4. J. Viral Hepat., 2008, 15: 710-715.
Sulkowski M.S., Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients J. Viral Hepat., 2007, 14: 371-386.
McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J. et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N. Engl. J. Med., 2009, 361: 580-593.
Bruno S., Shiffman M.L., Roberts S.K., Gane E.J., Messinger D., Hadziyannis S.J. et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology, 2010, 51: 388-397.
Charlton M.R., Pockros P.J., Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology, 2006, 43: 1177-1186.
Chuang W.L., Dai C.Y., Chang W.Y., Lee L.P., Lin Z.Y., Chen S.C. et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir. Ther., 2005, 10: 125-133.
Moreno C., Berg T., Tanwandee T., Thongsawat S., Van Vlierberge H., Zeuzem S. et al. Antiviral activity of TMC435 mono-therapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase Iia, open-label study. J. Hepatol., 2012, 56: 1247-1253.
Khattab M.A., Ferenci P., Hadziyannis S.J., Colombo M., Manns M., Almasio P.L. et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. Hepatology, 2011, 54: 1250-1262.
Pearlman B.L., Ehleben C., Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology, 2007, 46: 1688-1694.
Darling J.M., Fried M.W. Nitazoxanide: beyong parasites toward a novel agent for hepatitis C. Gastroenterology, 2009, 136: 760-763.
